Most undervalued S&P 500 — Health Care stocks
Updated Nov 21, 2026. 8 of 50 S&P 500 — Health Care constituents with an InvestorsCraft value are currently Undervalued or Strongly undervalued.
Valuation signal distribution
Signal bands are derived from published data.
Top 25 by valuation signal
| Rank | Ticker | Company | Price | Signal | IC value | Upside |
|---|---|---|---|---|---|---|
| 1 | INCY | Incyte Corporation | $114.63 | Strongly undervalued | Pro | Pro |
| 2 | XRAY | DENTSPLY SIRONA Inc. | $8.29 | Strongly undervalued | Pro | Pro |
| 3 | CI | Cigna Group | $270.90 | Strongly undervalued | Pro | Pro |
| 4 | BMY | Bristol Myers Squibb Company | $58.80 | Undervalued | Pro | Pro |
| 5 | BSX | Boston Scientific Corporation | $41.98 | Undervalued | Pro | Pro |
| 6 | HCA | HCA Healthcare, Inc. | $475.57 | Undervalued | Pro | Pro |
| 7 | UHS | Universal Health Services, Inc. | $179.43 | Undervalued | Pro | Pro |
| 8 | ZTS | Zoetis Inc. | $79.11 | Undervalued | Pro | Pro |
| 9 | ZBH | Zimmer Biomet Holdings, Inc. | $101.10 | Fairly valued | Pro | Pro |
| 10 | PFE | Pfizer Inc. | $27.40 | Fairly valued | Pro | Pro |
| 11 | REGN | Regeneron Pharmaceuticals, Inc. | $920.69 | Fairly valued | Pro | Pro |
| 12 | CNC | Centene Corporation | $63.78 | Fairly valued | Pro | Pro |
| 13 | DVA | DaVita Inc. | $161.03 | Fairly valued | Pro | Pro |
| 14 | HSIC | Henry Schein, Inc. | $83.52 | Fairly valued | Pro | Pro |
| 15 | RMD | ResMed Inc. | $235.63 | Fairly valued | Pro | Pro |
| 16 | COO | The Cooper Companies, Inc. | $58.88 | Fairly valued | Pro | Pro |
| 17 | ALGN | Align Technology, Inc. | $155.17 | Fairly valued | Pro | Pro |
| 18 | AMGN | Amgen Inc. | $435.64 | Fairly valued | Pro | Pro |
| 19 | BIIB | Biogen Inc. | $249.59 | Fairly valued | Pro | Pro |
| 20 | MRK | Merck & Co., Inc. | $133.72 | Fairly valued | Pro | Pro |
| 21 | SYK | Stryker Corporation | $310.00 | Overvalued | Pro | Pro |
| 22 | GILD | Gilead Sciences, Inc. | $166.43 | Overvalued | Pro | Pro |
| 23 | CVS | CVS Health Corporation | $80.84 | Overvalued | Pro | Pro |
| 24 | UNH | UnitedHealth Group Incorporated | $339.85 | Overvalued | Pro | Pro |
| 25 | ABT | Abbott Laboratories | $103.00 | Overvalued | Pro | Pro |
Full ranked list with exact values
The complete ranked list with exact intrinsic values and upside percentages is available with a Pro subscription.
How this list works
Each stock is ranked by its valuation signal: the difference between its price and its InvestorsCraft intrinsic value estimate. The intrinsic value comes from the model described on the valuation model page. Signals are derived figures — the exact intrinsic value is part of a Pro subscription. This list is a signal, not a recommendation to buy or sell any security.
Related
S&P 500 — Health Care constituents and index valuation · Most undervalued S&P 500 — Financials stocks · Most undervalued S&P 500 — Information Technology stocks · Most undervalued S&P 500 — Energy stocks · Most undervalued S&P 500 — Communication Services stocks · Most undervalued S&P 500 — Consumer Discretionary stocks · Most undervalued S&P 500 — Consumer Staples stocks
Questions about this list
How many S&P 500 — Health Care stocks are undervalued right now?
8 of the 50 S&P 500 — Health Care constituents with a published InvestorsCraft intrinsic value are currently rated Undervalued or Strongly undervalued, based on data updated Nov 21, 2026.
What does the undervalued signal mean?
The signal band compares the stock's price with its InvestorsCraft intrinsic value: Undervalued means the intrinsic value is 20–50% above the price, and Strongly undervalued means more than 50% above. The exact intrinsic value and upside percentage are available with a Pro subscription.
Why is a stock missing from this S&P 500 — Health Care list?
Only live S&P 500 — Health Care constituents with a published intrinsic value and a positive price are ranked. Stocks without a current valuation, or whose constituents list entry is stale, are excluded rather than shown with stale data.
Disclaimer: valuation signals are derived figures provided for educational purposes only, not investment advice.